Study Shows that Cervical Cancer Drug Can Protect for Over Six Years

A vaccine for reducing the risk of cervical cancer, Cervarix, has been found to remain effective for over six years when protecting against two high-risk types of HPV, the virus which is the primary cause of cervical cancer.

Every year, approximately 12,000 women develop cervical cancer as a result of an HPV infection, which makes cervical cancer the most common form of cancer associated with HPV. Other cancers resulting from an HPV infection include vulva cancer, vaginal cancer, penile cancer and anal cancer.

Cervarix is recommended for girls age 11 and 12, and for females 13 to 26; although it has been given to girls as young as nine.

In the study that examined the efficacy of Cervarix, the drug showed between 95 and 100 percent efficacy for up to 6.4 years against infection with the HPV16 and HPV18 virusus and against precancerous or cancerous changes to the cervix in girls and women between 15 and 25 years.

For free information about cervical cancer, see the cervical cancer medical malpractice attorneys of Pittsburgh, Pennsylvania.